CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Percutaneous Support Devices for Percutaneous Coronary Intervention Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study Considerations for Single-Measurement Risk-Stratification Strategies for Myocardial Infarction Using Cardiac Troponin Assays Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial

Guideline2016 Nov;152(5):1243-1275.

JOURNAL:J Thorac Cardiovasc Surg. Article Link

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Levine GN, Bates ER, Bittl JA et al. Keywords: AHA; P2Y(12) inhibitor; Scientific Statements; acute coronary syndrome; aspirin; coronary artery disease; coronary stents; dual antiplatelet therapy (DAPT); focused update; stable ischemic heart disease

FULL TEXT PDF